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CObjective: Clinical trials of new agents to reduce the severity and impact
of influenza require accurate assessment of the effect of influenza infec-
tion. Because there are limited high-quality adult influenza Patient Re-
ported Outcomes (PRO) measures, the aim was to develop and validate a
simple but comprehensive questionnaire for epidemiological research
and clinical trials.Methods: Construct and itemgenerationwas guided by
he literature, conceptmapping, focus groups, and interviewswith individu-
ls with laboratory-confirmed influenza and expert physicians. Items were
dministered to 311peoplewith influenza-like illness (ILI) across 25US sites.
nalyses included classic psychometrics, structural equation modeling
SEM), and Rasch analyses. Results: Concept mapping generated 149
oncepts covering the influenza experience and clustered into symp-
oms and impact on daily activities, emotions, and others. Items were
rafted using simplicity and brevity criteria. Eleven symptoms from
he literature underwent review by physicians and patients, and two
ere removed and one added. The symptoms domain factored into O
rpe&
i B. G
on of
irecto
y, M
al So
oi:10.1016/j.jval.2010.12.005ystemic and respiratory symptoms, whereas the impact domains
ere unidimensional. All domains displayed good internal consistency
Cronbach   0.8) except the three-item respiratory domain ( 0.48). A
ve-factor SEM indicated excellent fit where systemic, respiratory, and
aily activities domains differentiated patients with ILI or confirmed in-
uenza. All scales were responsive over time. Conclusions: Patient and
linician consultations resulted in an influenza PROmeasurewith high
alidity and good overall evidence of reliability and responsiveness.
he Influenza Intensity and Impact Questionnaire (FluiiQ™) will im-
rove the evaluation of existing and future agents designed to prevent
r control influenza infection by increasing the breadth and depth of
easurement in this field.
eywords: clinical trial, influenza, patient-reported outcomes, psycho-
etrics, surveillance, questionnaire validation.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Influenza clinical trials usually focus on outcomes such as labora-
tory-documented infection using viral culture and/or increase in
antibody titers to influenza antigens [1–3]. In drug and vaccine
trials, however, new agents are not expected to prevent infection;
rather, they are expected to reduce severity and duration of symp-
toms (e.g., fever, cough, malaise) functional impact, and time to
return to daily activities. To determine the efficiency or effective-
ness of investigational agents on influenza severity, patient-
reported outcomes (PROs) are used as primary and secondary end
points in clinical trials. Psychometric properties of PRO measures
are now commonly evaluated by regulatory authorities to ensure
that they generate reliable evidence to inform decisions regarding
the safety and efficacy of a new product [4].
The release of the US Food and Drug Administration guidance
(FDA) “Patient-Reported Outcome Measures: Use in Medical Prod-
Conflicts of interest: This researchwas sponsored byMerck Sha
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MSD and led all scientific aspects of the construction and validati
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098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.uctDevelopment to Support Labeling Claims” [4] inDecember 2009
significantly raised the level of rigor required for the development
and validation for all PRO measures included in clinical trials to
support labeling claims. Questionnaires accepted by regulatory
bodies before the release of the FDA guidance are now facing new
scrutiny because they may be lacking in several of the required
development and validation factors. One such factor, content va-
lidity, has been repeatedly recognized as a critical step in estab-
lishing the validity of the items used in measures based on
patient self-report. The guidance points to the need for direct
patient input during the development and refinement items in
PROmeasures. It requires all items, response options, and recall
periods to be demonstrated as relevant and important to pa-
tients with the particular disease or illness assessed by themea-
sure.
There are limited high-quality adult PRO measures available
and even fewer validated PRO measures on influenza symptom
Dohme (MSD) Corp. The following authors are employees ofMSD:
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the FluiiQ.
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688 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9severity and impact. After an extensive literature review, al-
though there is one well-validated acute respiratory illness
scale in children [5], to the knowledge of the authors, the only
validated adult PROs in this area are the Influenza Symptom
Severity Scale (ISS) and the Influenza Impact Wellbeing Scale
(IIWS) questionnaires [6]. These measures were developed in
2000 to measure the symptoms and impact of influenza. These
questionnaires were developed based on literature review and
physician input and were shown to have evidence of internal
consistency and construct validity. Given, however, the FDA
guidance documents discussed previously [4,7], these question-
naires had some shortcomings, including the absence of con-
sultation with patients in the development of the questions,
absence of cognitive testing of questions, and inadequate test-
ing in individuals with laboratory-confirmed influenza.
The aim of this study was to develop and validate a compre-
hensive measure of the symptoms and impact of influenza on
individuals with influenza-like illness (ILI) and laboratory-con-
firmed influenza for use in epidemiological studies and trials of
vaccine and pharmaceutical agents.
Methods
To improve on the previously developed ISS and IIWS [6], ques-
ionnaire development studies were conducted from May 2005
hrough November 2006 and consisted of the following: 1) influ-
nza expert physician consultations; 2) conduct of the Item and
uestionnaire Development Protocol, which consisted of patient
ankings of bothersomeness of individual symptoms, patient con-
ultation using concept mapping [8] in Australia, and a traditional
ocus group in the United States; 3) development of a conceptual
odel; and 4) patient cognitive testing of newly developed scales.
ethods for each activity are briefly outlined below in the follow-
ng. An area of impact that we did not seek to cover in the con-
truct development was the impact of influenza on working and
ssociated economic impacts. These impacts were omitted be-
ause we regarded them as being adequately covered by other
ools (e.g., employment and cost diaries).
Expert physician consultations
Expert physician views were sought to elicit feedback on symp-
toms that patients with influenza experience and the impact
that influenza has on patient well-being. We also sought feed-
back on the relevance and wording of items included in the two
candidate measures (ISS and IIWS). Semistructured telephone
interviews were conducted by an experienced interviewer with
six general physicians in the United States with familiarity with
treating patients with influenza and one physician with exten-
sive influenza academic research experience. An interview
guide was used to ensure that key topics were covered, but it
was not adhered to verbatim. Experts were chosen based on
recommendations made by the Merck Research Laboratories
clinical team, by field monitors, or by geographic location. Ex-
perts were not compensated for their time, and interviews were
not audio-recorded. Field notes were taken by two observers as
well as by the interviewer.
Item and questionnaire development study protocol
Participants 18 years of age and older with ILI (defined as fever
37.8°C plus at least one of the following symptoms: cough, sore
throat, runny nose, or muscle aches on one day or, in the absence
of fever, the presence of at least two of these symptoms of mod-
erate severity for two consecutive days) were enrolled from gen-
eral practitioners and health clinics in the United States and Aus-
tralia. Independent ethical review committees at each study site
approved the study protocol, and all participants providedwritteninformed consent. At the time of enrollment, to explore the con-
tent validity of the symptoms within the ISS and the degree to
which patients endorse the items, patients with ILI rated each
symptom on both importance and bothersomeness on 6-point
scales (i.e., from 0 [not at all bothersome] to 5 [very bothersome]).
Patients were able to list additional symptoms in an open-ended
“other” category. Bothersomenesswas only assessed for the ISS as
it was specific to symptom severity and therefore was not con-
ducted for the IIWS components. Bothersomeness scoreswere an-
alyzed and reported as ranks, frequencies, and means with SD.
After enrollment in the studywas completed, those patients found
to have laboratory-confirmed influenza infection took part in a
separate focus group. Laboratory-confirmed influenza infection
was defined as any participant who was positive for influenza
infection via viral culture and/or by a fourfold or more increase in
hemagglutinin inhibition antibody titer. Patient focus groupswere
one traditional focus group conducted in the United States and
three concepts mapping workshops (see later), conducted in Aus-
tralia. The recall period between enrollment in the study and focus
groups (traditional and conceptmapping) did not exceed 5months
for all patients.
Traditional focus group (United States)
Based on enrollment into the questionnaire development pro-
tocol conducted in the United States, and described previously,
patients were identified as having laboratory-confirmed influ-
enza at the University of Virginia student health clinic and sub-
sequently were enrolled in a focus group. The objectives of the
focus group were to ask patients to describe the constellation of
symptoms caused by their current influenza episode, identify
areas of their lives affected by influenza as well as obtain direct
feedback on the ISS and IIWS questionnaires. The focus group
was facilitated by an external vendor using a standard focus
group guide.
Concept mapping workshops (Australia)
Based on enrollment in the questionnaire development proto-
col conducted in Australia, and described previously, patients
were identified as having laboratory-confirmed influenza at two
general practitioner clinics in Brisbane, Melbourne, and Sydney
and subsequently enrolled in concept mapping workshops.
Concept mapping, which includes a structured nominal group
process and is well suited to questionnaire development [8,9],
was undertaken to identify broad potential impacts of influenza
on people and generate potential questionnaire items [9–11].
Participants were asked to respond to the following seeding
statement: “Thinking as broadly as possible, generate state-
ments to describe how your recent episode of flu affected you
and your life.” Responses were printed on individual cards, and
participants were then required to intuitively sort them into
categories. Participants were also asked to rate each response
according to two dimensions: impact and duration. The sort
data were then analyzed during the workshop using specialized
software (Concept System software, Concept Systems Inc., New
York, and ClustanGraphics, Clustan Limited, Edinburgh), which
uses two multivariate statistical methods (multidimensional
scaling and cluster analysis) to analyze the patterns among
statements generated and subsequently sorted by participants.
The outcome of this process provides a visual map that groups
responses into clusters. The final step involves displaying the
map to participants who are asked to come to a consensus
around the meaningfulness of statement groupings (i.e., clus-
ters) and identify overarching descriptors of the underlying
theme of each cluster.
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Theconceptswithineachbroadcluster informedthedevelopmentof
items. Where possible, the patient’s original wording was preserved
for content validity. Itemgenerationwas highly structuredwith con-
stant reference to how a personwith influenzamay respond to each
item.Each itemhadtobesuccinctandconcisebecausepatientscom-
pleting questions might be quite ill. The content had to be relevant
across disease severity and to the broad target population (e.g.,
across age, sex, education, and language groups).
Concepts were submitted to a restricted set of experts, includ-
ing three psychometricians, five epidemiologists, two statisti-
cians, and amedical editor for review. After numerous revisions, a
final set of items for the PROmeasure within each target construct
was derived through consensus by the experts in a full-day face-
to-face workshop.
Development of a conceptual model of symptoms and impact
of influenza
Based on the literature review, physician consultations, tradi-
tional focus group, and concept mapping results, a causal model
was conceived to guide questionnaire development and the
subsequent examination of construct validity. It was proposed
that an infection would result in symptoms being caused by the
pathophysiology of the disease. These symptoms then affect
function in several ways, namely, through physical activities,
emotions, and psychosocial factors (Fig. 1). The focus of the
measures being developed was limited to the inclusion of prox-
imal effects (symptoms and immediate impact of these symp-
toms) rather than further downstream effects such as economic
burden. With a model established a priori, a subsequent finding
of robust factorial separation of items into factors together with
empirical support for the causal model would provide evidence
of construct validity [12].
Cognitive testing
Once items were derived using the described procedures, each
item and the overall format of the questionnaire underwent cog-
nitive testing. As the target population of the questionnaire is pa-
tients with ILI or confirmed influenza infection, a general sample
of peoplewho reported having had physician-diagnosed influenza
infection within the past 3 years were recruited for participation.
Subjects were asked to review the study materials and then par-
ticipate in in-depth, individual semistructured interviews. Partic-
ipants were asked to provide their understanding of words and
phrases and comment on the instructions, the ease of completion,
and the appropriateness of response options. The interviewswere
not recorded; however, comprehensive notes were taken.
Questionnaire validation
Questionnaire validation protocol
People 18 years of age and older were recruited across 25 US sites
including general practitioner offices, outpatient health clinics
(hospital or community), and university health clinics. Patients
were included if they presented within 48 hours of onset of ILI as
defined previously. Using a computer-generated series of randomFig. 1 – Causal model of the impact of influenumbers, patients were assigned with equal probability to receive
the questionnaire in a paper-based format or in an electronic in-
teractive voice response system format once per day for 14 days.
The equivalence of these delivery modes will be the subject of
future reports. Data from day 1 were used for structural equation
modeling (SEM) and Rasch analyses (described in the following). A
central institutional review board was used to obtain ethics com-
mittee approval across all sites, and all participants providedwrit-
ten informed consent.
Patients assessed and recorded the level of their symptoms
daily throughout the 14 days of the study. Additionally, patients
and physicians were asked to assess overall severity of symptoms
using the Patient or PhysicianAssessment of Global Severity Ques-
tion (GSQ) (4-point scale ranging from 0 [none] to 3 [severe]). The
global severity questionswere completed at days 1, 7, and 14 (days
1 and 14 only for physicians). Patients completed the EQ5D ther-
mometer (www.euroqol.org/home.html), awidely used generic vi-
sual analogue measure of health-related quality of life (QoL) with
anchors from 0 (worst imaginable health state) to 100 (best imag-
inable health state). This was measured on days 1 and 14. A ge-
neric global health question (GGHQ) was also completed by pa-
tients; it asked patients to rate their current health status on a
5-point scale (i.e., excellent, very good, good, fair, poor; coded 0 to
4). This was completed on days 1, 7, and 14.
Statistical methods
Descriptive statistics were generated for each item to determine
the extent of missing values and floor and ceiling effects across
domains. Extreme scores were classified as the bottom decile of a
domain score (i.e., 0.3 where the scale range is from 0.0 to 3.0);
conversely ceiling effects were the top decile of a domain (i.e.,
score  2.7).
Missing data
A small number of discrete data points were missing for the ques-
tionnaire data. To maximize data for the SEM, values for missing
datawere imputed using the Expectation-Maximization algorithm
(SPSS version 12.0) and were rounded back to the nearest discrete
value. For the remaining analyses, missing data were treated us-
ing pairwise deletion, in which cases with missing values were
deleted on a variable-by-variable basis.
Factor analysis
Confirmatory factor analysis (CFA) was undertaken with Mplus
(version 6.1) to determine whether hypothesized latent variables
representing dimensions loaded on the specified items. A se-
quence of one-factor models and a final multifactor model were
fitted to the data. The models were fitted following the general
method for the analysis of ordinal data using polychoric corre-
lations recommended by Jöreskog [13] and the robust mean-
and variance-adjusted weighted least squares (WLSMV) estima-
tor available in Mplus. Preliminary studies of this approach to CFA
with categorical or ordinal data have suggested that it performs
well with relatively small samples [14].
Judgments of how well the data fitted the CFA and the resulting
SEM models were evaluated using goodness-of-fit statistics. For anza infection on affected individuals.
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690 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9reasonably good fit, the following criteria were used [15,16]: root
meansquareerrorofapproximation (RMSEA)0.08 foranacceptable
fit and 0.05 for a good fit; confirmatory fit index (CFI) and Tucker-
Lewis index (TLI) 0.95; 2/df  2.0; and weighted root mean square
esidual (WRMR)1.00.
Criteria to judge whether the estimates of association between
actors, items, and error terms were substantive included:
. Loadings of factors on items 0.50 were regarded as low. Fur-
ther assessment included whether the loadings of each item
within a factor were approximately similar.
. Individual correlations between residual errors of items were
regarded as substantial if they were 0.15. Correlations be-
tween residuals suggesting that there may be a more complex
factor structure than that hypothesized and subfactors were
then explored.
. Correlations between factors were regarded as excessive if they
were 0.90.
Rasch analysis
Rasch analyses using RUMM2020 [17] were conducted to explore
item characteristics and further test construct validity of do-
mains [18]. The Rasch model summarizes the relationship be-
tween the characteristics of an item and the characteristics of
an individual in terms of probability of endorsing an item of a
given difficultly (the extent to which the item is difficult to agree
with) by a person of certain ability (level of underlying trait).
Construct validity of a scale is supported when the data have
good fit with the Rasch model. Assessment of fit of a domain
was based on item-trait interaction 2 and Person Separation
ndex (PSI). Good model fit is indicated by a nonsignificant 2
value and is achieved when the endorsement of higher re-
sponse options is uniformly associated with higher levels of an
underlying trait. A PSI indicates a domain’s ability to discrimi-
nate between the levels of an underlying trait, with values of
0.80 indicating good discriminability. Fit of individual items
was assessed using fit residuals and item 2, both of which repre-
ent the differences between the observed pattern of responses for
he item and the pattern of responses predicted from the Rasch
odel. Poor item fit is suggested by significant 2 and fit residual
values2.5 (indicative of redundant items) and2.5 (suggesting
item content is incongruent within a domain).
Rasch analysis was also used to assess item threshold ordering
and differential item functioning (DIF). Thresholds define the
boundaries between the item response option categories and rep-
resent the level of the trait being measured such that the proba-
bility of choosing either of the adjacent response categories is 0.5
[19]. Disordered thresholds are undesirable because they tend to
occurwhen respondents have difficulty in discriminating between
response options such as when response options are ambiguous
or do not clearly represent different intensity of symptoms. Disor-
dered thresholds can also be due to item content that is ambigu-
ous or double-barreled. DIF, indicated by significant F-ratios from
analysis of variance, suggests that an item is not unidimensional
and that characteristics other than levels of the underlying trait
may be influencing the respondent’s answers. DIF was assessed
across subgroups based on age, sex, race, and influenza status
(confirmed influenza vs. ILI). Bonferroni corrections (  0.05/
umber of domain items) were applied to all Rasch model analy-
es.
To investigate whether one or more items do not relate to the
ntended construct within a scale, principal components analysis
f residual correlations (PCARC) was conducted [20]. PCARC in-
olves analysis of item residuals to identify the presence of sec-
ndary variables that could potentially account for the correla-
ions among items after removing variance due to the primary
onstruct (i.e., influenza symptoms).Reliability, discriminant and convergent validity, known
groups validity, and responsiveness
Once the items and domains were confirmed, internal consis-
tency was assessed with Cronbach’s  coefficients where good
internal consistency is defined as an  coefficient 0.70 [19].
Discriminant and convergent validity (elements of construct va-
lidity) was assessed by examining the association between the
Influenza Intensity and Impact Questionnaire (FluiiQ™) do-
mains and the other measures included in the validation study.
Specifically, to assess construct validity, Spearman’s correla-
tion coefficients were obtained between the FluiiQ™ and the
Patient and Physician GSQ, the EQ5D thermometer, and the
GGHQ. It was hypothesized that correlations would bemoderate
with the FluiiQ™ positively correlated with the Patient and Phy-
sician GSQ, and the GGHQ and negatively correlated with the
EQ5D thermometer. The range used to qualify the strength of
correlations between the FluiiQ™ and other measures was: r 
0.25  weak; 0.25 to 0.75  moderate; r  0.75  strong [21,22].
Known group validity was evaluated by comparing partici-
ants with confirmed influenza with those with ILI across all do-
ains using means and 95% confidence intervals (CIs). It was ex-
ected that those with confirmed influenza would report higher
cores across all domains than those with ILI. To assess respon-
iveness, change () from day 1 to day 14 was used to calculate
ffect size (ES: mean /SD at day 1) and standardized response
ean (SRM:mean /SD of ). An effect size with an absolute value
0.8 is indicative of good responsiveness [22].
Results
Item development
Physician consultations
Six general practitioners and one expert influenza researcher
were consulted and identified common influenza symptoms in-
cluding febrile illness (sudden onset), body aches (both myalgia
and arthralgia), headache, sore throat, neck pain, chills, ex-
treme fatigue (significant disability), cough, dizziness, malaise,
as well as lack of appetite. Gastrointestinal symptoms (nausea,
vomiting) were usually regarded as secondary to other infec-
tions. All physicians commented that although there is a “typ-
ical” constellation of influenza symptoms, these may vary in
frequency and severity, depending on the particular strain and
host factors. All physicians indicated that the level of prostra-
tion was a good indicator of symptom severity. All noted that
influenza involved a gradual reduction of each symptom until a
return to daily activities. Several physicians noted that symp-
toms such as a nagging cough may persist for 5 to 20 days after
initial infection.
Physicians also reviewed the ISS and IIWS questionnaires
[6]. They indicated that a 4-point scale was adequate to capture
the symptom intensity range (absent to severe). Of the 11 symp-
toms from the ISS, it was indicated that the symptom lack of
concentration was not sufficiently specific to influenza and was
not important to measure and, as noted previously, nausea was
likely to be secondary to other infections. Therefore, lack of
concentration and nausea were removed. Although the remain-
der of the items was endorsed, neck pain was raised as a new
item and included. Finally, they suggested the term nasal con-
gestion was potentially difficult for some patients. There was
agreement that the three-item IIWS questionnaire (visual ana-
logue scales covering general health, global usual activities, and
sleep) poorly captured the impact of influenza. Some anchors
for the scales were regarded as potentially objectionable, for
example one anchor was “worse than being dead.” It was agreed
691V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9that this scale needed redevelopment to capture the true impact
of influenza on patients.
Bothersomeness rating of symptoms
A total of 67 patients provided a bothersomeness rating of candidate
symptoms. Of these, 23 were culture-confirmed influenza cases and
25 were recruited in the United States. The four top-ranked items in
both groups (ILI and confirmed influenza) based on bother score in-
cluded feeling feverish, fatigue, achesandpains, anddisturbedsleep,
suggesting similar symptomprofiles for bothgroups.Nauseawas the
lowest ranked item in both groups and was least frequently en-
dorsed. Bother scores were higher in the top-ranked items for the
confirmed influenza group, suggestive of more severe symptoms in
this group compared with the ILI group (Table 1).
Fig. 2 – Concept map generated from people recently experie
Table 1 – Bothersomeness of influenza symptoms derived
influenza-like illness.
Draft item Confirmed influenza (n  23)
Frequency
endorsed
Bothersomeness,
mean (SD)
Bother sc
rating
Feverish 23 3.87 (0.97) 89
Fatigue 22 3.95 (1.13) 87
Aches and pains 23 3.70 (1.34) 85
Disturbed sleep 21 3.67 (1.01) 77
Nasal congestion 22 3.41 (1.18) 75
Cough 22 3.41 (1.50) 75
Headache 22 3.27 (1.20) 72
Sore throat 22 2.90 (1.15) 64
Poor concentration 20 2.80 (1.15) 56
Loss of appetite 20 2.20 (1.39) 44
Nausea 14 2.43 (1.34) 34the domains of influenza impact.Traditional focus group (United States)
Six participants, 19 to 31 years of age, identified a list of influenza
symptoms experienced during their recent influenza illness. They
identified fatigue and fever as the symptoms that bothered them the
most. Additionally, they identified themost significant impact of in-
fluenza as their inability to do daily activities (such as schoolwork
and social activities) and concentrate on tasks. Although they
thought that all symptoms in the ISS were relevant and the
questionnaire was easy to answer and clear, this was not the
case for the IIWS. They thought that the IIWS questions were
vague and difficult to answer due to unclear wording. There was
general agreement that it needed modification and additional
constructs added if it were to adequately capture the impacts of
influenza beyond direct symptoms, consistent with the physi-
g influenza symptoms with the group’s interpretation of
US and Australian samples with confirmed influenza or
Influenza-like illness (n  44)
Rank Frequency
endorsed
Bothersomeness,
mean (SD)
Bother score
rating
Rank
1 64 3.79 (1.02) 243 1
2 60 3.72 (1.16) 223 2
3 62 3.53 (1.31) 219 3
4 59 3.52 (1.19) 208 4
5 58 3.31 (1.44) 192 7
6 59 3.12 (1.23) 184 8
7 58 3.14 (1.26) 183 5
8 55 3.13 (1.29) 172 6
9 54 2.81 (1.18) 152 9
10 50 2.12 (1.20) 106 10
11 30 2.33 (1.15) 70 11ncinfrom
ore
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692 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9cian consultations. Based on the results of the US focus group, it
was decided that additional focus groups would be undertaken
during the upcoming Southern Hemisphere influenza season in
Australia in the form of concept mapping workshops to com-
prehensively redevelop the ISS and IIWS.
Concept mapping workshops (Australia)
Three workshops with 16 people, 21 to 55 years of age who had lab-
oratory-confirmed influenza in the past 5 months, were undertaken
in Australia (2 in Brisbane and 1 in Sydney). A total of 149 statements
were obtained in response to the seeding statement. The generated
maps (see Figure 2 for an example) enabled overarching concepts to
e identified.Concatenationof the threeworkshops involvedconsid-
ration of individual statement content, commonalities between the
escriptors generated, and consideration of the conceptual model
i.e., symptomsor theconsequenceof symptoms).Keydimensions to
merge included symptoms, impact on routine physical activities,
nd psychosocial aspects including emotional, social relationships,
nd economic concerns. Statements that did not reflect the seeding
Table 2 – Confirmatory factor analysis (CFA) and Rasch ana
Domain* CFA
Factor loading
Symptoms: systemic
c. Headache 0.608
e. Feeling feverish 0.763
f. Body aches 0.848
g. Fatigue . . . 0.782
h. Neck pain 0.736
i. Interrupted sleep 0.647
j. Loss of appetite 0.694
Symptoms: respiratory
a. Cough 0.537
b. Sore throat 0.477
d. Nasal congestion 0.617
CFA fit statistics (two-factor solution): 2  62.78, 33 df, P  0.0013; 2
Rasch fit statistics: respiratory symptoms: 2(6)  5.82, P  0.4, PSI 
Impact on daily activities
a. Get out of bed 0.814
b. Prepare meals . . . 0.962
c. Perform usual . . . 0.847
d. Leave the home . . . 0.886
e. Concentrate on . . . 0.807
f. Take care of . . . 0.925
CFA fit statistics: 2  14.08, 8 df, P  0.0631; 2/df  1.85; CFI  0.999;
Rasch fit statistics: 2(12)  22.28, P  0.035, PSI  0.92.
Impact on emotions
a. Irritable 0.677
b. Feel helpless 0.763
c. Worried 0.594
d. Frustrated 0.957
CFA fit statistics: 2  1.562, 2 df, P  0.458; 2/df  0.78; CFI  1.000; T
Rasch fit statistics: 2(8)  21.53, P  0.006, PSI  0.82.
Impact on others
a. People worrying . . . 0.780
b. Being a burden 0.986
c. People being . . . 0.782
d. Needing to depend . . . 0.879
e. People having to . . . 0.892
CFA fit statistics: 2  16.434, 4 df, P  0.0025; 2/df  2.44; CFI  0.998
Rasch fit statistics: 2(10)  52.77, P  0.001, PSI  0.90.
CFI, confirmatory fit index; RMSEA, root mean square error of approxim
* Items truncated; full items available from the author.tatementorwerenonspecificwere removed including “putneckoutfrom sneezing,” and “unexpected, didn’t see it coming.” Statements
were also removed if they were obscure or not direct impacts (“blis-
ters on face” and “irritation of teeth”). Statementswere also removed
if they related directly to economic and work effects because these
dimensions had been chosen a priori to not be part of the current
questionnaire.
Draft items, scales, and response options
The final domains and items are shown in Table 2, and in sum-
mary they included:
Influenza symptoms (10 items). This domain covered systemic
symptoms (headache, fever, body aches, fatigue, neck pain, sleep,
and appetite) and upper respiratory symptoms (cough, sore throat,
andnasal congestion). Responseoptions (0–3)werenone,mild,mod-
erate, and severe.
Impact on daily activities (6 items). This domain covered thephys-
of FluiiQ™ domains.
Rasch analysis
Fit residual 2 (df  2) 2 P value
Bonferroni corrected   0.007
1.61 3.61 0.164
0.14 1.76 0.415
2.13 7.17 0.028
1.17 2.94 0.230
0.07 1.24 0.538
1.90 0.83 0.662
1.56 0.01 0.993
Bonferroni corrected   0.017
0.21 4.09 0.130
1.01 0.93 0.627
0.97 0.80 0.672
1.90; CFI  0.983; TLI  0.977; RMSEA  0.057; WRMR  0.712.
Systemic symptoms: 2(14)  17.57, P  0.2, PSI  0.85.
Bonferroni corrected   0.008
2.73 6.25 0.044
3.07 7.87 0.020
0.06 0.38 0.829
0.09 1.41 0.493
1.31 0.62 0.733
1.57 5.74 0.057
0.998; RMSEA  0.055; WRMR  0.412.
Bonferroni corrected   0.013
2.42 5.52 0.063
0.19 4.42 0.110
0.51 4.49 0.106
2.05 7.10 0.029
1.002; RMSEA  0.000; WRMR  0.196.
Bonferroni corrected   0.01
3.12 7.93 0.019
3.87 17.72 0.001
3.16 9.79 0.007
–2.36 7.97 0.019
2.13 9.36 0.009
 0.996; RMSEA  0.105; WRMR  0.484.
; TLI, Tucker-Lewis index; WRMR, weighted root mean square residual.lysis
/df 
0.51.
TLI 
LI 
; TLI
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693V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9form routine or normal activities. This encompasses an individual’s
ability to look after themselves, mobility, and concentration. Re-
sponseoptions (0–3) includednodifficulty, somedifficulty,moderate
difficulty, and great difficulty.
Impact on emotions (4 items). This domain covered the range of
egative emotions related to having influenza and included irritabil-
ty, helplessness, worry, and frustration. Response options (0–3) in-
luded not at all, somewhat, moderately, and extremely.
Impact on others (5 items). This domain covered the concerns,
train, or burdenpresent in relationships between the individual and
eople around them (e.g., family/friends/neighbors) as a result of in-
uenza. Ratings (0–3) included not at all concerned, somewhat con-
erned, moderately concerned, and extremely concerned.
Cognitive testing
The content of the final set of questions was tested by patients
participating in focus groups. The participants further judged the
content to be relevant and important to people with influenza.
Although almost all questions were easily understood, there was
some concern that sore throat and neck pain may have had con-
ceptual overlap, but ultimately these were regarded as distinct
symptoms by all subjects. Sore throat was described as internal
and related to swallowing, whereas neck pain was depicted as
muscular in nature. Neck pain also was differentiated from aches
and pains as a distinct symptom. About half of the subjects indi-
cated that adding “body” to “aches and pains” would improve the
specificity the item. The fatigue symptom contained the paren-
thetical expression “tiredness,” and all subjects thought that it
helped clarify the question.Within the Impact scales, the intent of
the item “have your meals” was interpreted slightly differently by
some subjects. Some thought that it related to simply eating
meals, whereas others thought that the question was about pre-
paring meals. Additionally, some subjects noted that one might
not cook or prepare foods but rely on prepackaged meals, espe-
cially when ill. This item was therefore expanded to include “get
your own food.” There was some discussion about the “being a
burden” item, and it was deemed to bemore strongly worded than
“needing to depend on people.” Those two items, however, were
considered to be independent and different, and no revision was
regarded as necessary. All response options and instructions were
found to be clear and appropriate.
Validation study
A total of 311 participants were enrolled across 25 sites in the
United States. The median age was 40 years (range, 18–84 years),
and 64% were female. The majority had completed high school
(60%), were working full time (67%), andwere white (72%white
13% Hispanic, 11% black, and 4% Asian/other) (Table 3). Demo-
graphic factors were evenly distributed across those with ILI ver-
sus those with confirmed influenza. Influenza status was known
for 263 (85%) of the sample; 57% had ILI and 28% had confirmed
influenza. True influenza status could not be confirmed for 15% of
patients with ILI due tomissing serology and/or culture results. Of
the 311 enrolled, 18 (5.8%) did not complete any of the question-
naires and were removed from the analyses, leaving 293 cases. At
day 1, missing data points for each items ranged from 11 (3.8%) to
14 (4.8%) across items. At day 14, the proportion of cases with
missing data ranged from 9.6% to 10.9% across items.
At day 1, the only domain with substantial floor effects was im-
pact on others where 28.4% of respondents were in the low range.
There were minimal ceiling effects for all domains, indicating that
most respondents did not score “severe” across all items. Systemic
symptoms were the most intense for respondents, where 12.4% re-
ported scores in the upper decile (Table 4).CFAs
Symptoms domain. CFA of the 10 items of the symptoms domain
esulted in a modest fit. Three items were only weakly loaded by
he single latent variable (cough, sore throat, and nasal conges-
ion), and correlated errors among these items suggested a subfactor
data not shown). A two-factor solution (respiratory symptoms and
ystemic symptoms) resulted in a very good fit (Table 2). The corre-
ation between the factors was moderate (r  0.58). All items had
significant loadings from their respective latent variables, and the
lowest loading itemwas sore throat (r 0.48). Therewas onemodest
orrelated residual between headache and neck pain (r  0.24), a
ogical connection given the close physical proximity of these
ensations.
Impact on daily activities domain. CFA of the impact on activities
omain resulted in an excellent fit. All itemswere loaded strongly by
he latent variable (0.81). Therewas onenotable correlated residual
between “perform usual activities” and “concentrate on tasks,” r 
.36), again a logical connection suggesting that loss of concentration
ay affect task completion.
Impact on emotions domain. CFA of the impact on emotions do-
main also resulted in an excellent fit. All items loaded satisfacto-
rily (0.59), and there were no statistically significant correlated
residuals.
Impact on others domain. CFA of the impact on others domain
ielded a problematic fit. Although all itemshad satisfactorily high
oadings (0.78), there was one large correlated residual between
needing to depend on people” and “people having to do extra
hings for you,” r  0.63), suggesting a significant level of redun-
ancy between these two items.
SEM
Ameasurementmodelwith five factorswas specified as follows: 1)
each construct was constrained to load only on the items that
were hypothesized to be associated with it (i.e., no cross-loadings
were allowed); 2) there were no correlations among the item re-
Table 3 – Validation study: demographic background
of people with influenza-like illness and confirmed
influenza.
Influenza-like
illness
Confirmed
influenza
All
Age, y, mean (SD) 43.3 (15.8) 41.1 (12.3) 42.1 (14.9)
Sex, female, no. (%) 119 (67.2) 52 (60.5) 199 (64.0)
Race, no. (%)
White 126 (71.2) 67 (77.9) 193 (73.4)
Hispanic American 25 (14.1) 1 (1.2) 26 (9.9)
Black 18 (10.2) 8 (9.3) 26 (9.9)
Asian 6 (3.4) 7 (8.1) 13 (4.9)
Indian (subcontinent) 1 (0.6) 2 (2.3) 3 (1.1)
Native American 1 (0.6) 1 (1.2) 2 (0.8)
Income, no. (%)
$15,000 15 (8.5) 5 (5.9) 20 (7.6)
$15,000–$24,999 22 (12.4) 5 (5.8) 27 (10.3)
$25,000–$34,999 22 (12.4) 15 (12.8) 37 (14.1)
$35,000–$49,999 38 (21.5) 18 (17.4) 56 (21.3)
$50,000–$74,999 32 (18.1) 12 (20.9) 44 (16.7)
$75,000–$99,999 18 (10.2) 11 (14.0) 29 (11.0)
$100,000 10 (4.0) 8 (9.3) 18 (6.8)
Not available 20 (11.3) 11 (12.8) 31 (11.8)siduals; and 3) correlations between factors were freely estimated.
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694 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9This model fitted the data reasonably well (CFA fit statistics: 2 
486.06, 265 df; P  0.0001; 2/df  1.83; CFI  0.984; TLI  0.982;
RMSEA 0.057;WRMR 0.928). The fit improvedwith the addition
of correlations between the residuals of headache and neck pain,
perform normal activities and concentrate on tasks, and needing
to depend on people and people having to do extra things for you
(2  448.06, 262 df, P  0.0001; 2/df  21.71; CFI  0.986; TLI 
.985; RMSEA  0.052; WRMR  0.871) but the fit could not be
appreciably improved further. Correlations among the factors
ranged from r  0.46 between respiratory symptoms and impact
n emotions to r  0.86 between impact on emotions and impact
n others.
A finding of robust factorial separation of items into factors fol-
owing theoretical specification, as shown previously, provides
trong support, but isnot sufficient for construct validity [12].What is
lso required is functional separation in the nomological network of
he constructs, i.e., differential prediction of important outcomes. To
est this causal model based on the five factors with paths between
hemguidedby theconceptualmodelwas specifiedas follows: 1) one
xogenous source of variation in reported respiratory and systemic
ymptoms was hypothesized: confirmed influenza versus ILI; 2) re-
piratory and systemic symptoms were subsequently hypothesized
Table 4 – Psychometric characteristics of the FluiiQ™.
Characteristic Sy
All Syste
Cronbach’s  (reliability)* 0.82 0.8
Ceiling and floor effects: day 1
Proportion in lower 10% of domain (score  0.30) 0.0 1.4
Proportion in top 10% of domain (score  2.7) 5.7 12.4
Magnitude of change: day 1 to day
14 (responsiveness to change)†
Day 1
Mean 1.80 1.7
SD 0.58 0.6
Day 14
Mean 0.33 0.3
SD 0.43 0.4
Average individual change 1.53 1.4
Effect size‡ 2.66 2.1
SD of change 0.67 0.7
Standardized response, mean 2.28 1.9
Change over time across groups
(responsiveness to change)§
Confirmed cases of influenza
Mean change: day 1 to day 14 1.74 1.8
SD of change 0.55 0.6
Standardized response, mean 3.19 2.9
Influenza-like illness
Mean change: day 1 to day 14 1.46 1.4
SD of change 0.69 0.7
Standardized response mean 2.12 1.9
Difference between confirmed influenza
and influenza-Iike illness
Day 1, mean 0.23 0.2
95% CI, upper 0.38 0.4
95% CI, lower 0.08 0.0
CI, confidence interval.
* Sample size: N  276 to 282 across domains.
† Sample size: N  258 for symptoms and 254 for impact domains.
‡ ES  (change from day 1 to day 14)/SD at day 1.
§ Sample size: confirmed influenza, n  75 for symptoms, n  7
domains.o be causally related to daily activities, impact on emotions, and impact on others; 3) no causal paths or correlations between indica-
ors and factors or indicators and indicators with the exception of
hree residual correlations specified previously were allowed. After
stimating the model with all causal paths specified previously,
hose that were not statistically significant (P  0.05) were deleted,
nd themodelwasestimatedagain.The resultingstatistics indicated
very good fit (2 498.23, 288 df, P 0.0001, 2/df 1.73, CFI 0.985,
LI  0.983, RMSEA  0.053, WRMR  0.915). Statistically significant
P  0.05) causal associations were found between: confirmed influ-
nza versus ILI and systemic symptoms (0.19; those with confirmed
nfluenza reported more severe systemic symptoms); systemic
ymptoms and impact on daily activities (0.81); systemic symptoms
nd impact on emotions (0.71); systemic symptoms and impact on
thers (0.51); and respiratory symptoms and impact on others (0.18).
otably, no causal associations between confirmed influenza and
espiratory symptoms and respiratory symptoms and impact on
aily activities or impact on emotions were observed. Additionally,
ny causal association between confirmed influenza and impact on
aily activities, emotions, and others was mediated through influ-
nza symptoms.
The error variances associated with the outcome factors
howed that the model accounted for 66% of the variance in
ms Impact on daily
activities
Impact on
emotions
Impact on
others
Respiratory
0.48 0.92 0.85 0.91
0.0 6.0 13.8 28.4
8.5 9.6 3.5 5.3
1.85 1.45 1.28 1.00
0.63 0.84 0.82 0.85
0.42 0.08 0.14 0.08
0.57 0.25 0.36 0.25
1.56 1.36 1.13 0.92
2.49 1.62 1.38 1.07
0.75 0.86 0.80 0.83
2.08 1.58 1.42 1.10
1.60 1.64 1.20 0.93
0.60 0.85 0.77 0.75
2.67 1.94 1.54 1.24
1.40 1.28 1.13 0.94
0.79 0.86 0.82 0.88
1.76 1.49 1.37 1.07
0.12 0.38 0.07 0.05
0.29 0.60 0.29 0.28
0.05 0.12 0.16 0.18
impact domains; ILI, n  159 for symptoms, n  156 for impactmpto
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695V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9in impact on others. The amount of variance explained in these
domains is quite substantial and indicates that the symptom
domains are indeed pertinent to an individual’s health state
and, in particular, strongly determine the activities, emotions,
and relationships of affected individuals.
Flu status (confirmed vs. ILI) was only weakly and positively
associatedwith systemic symptoms and not related to respiratory
symptoms. The data indicate that influenza status explains only
about 4% of the variance in systemic symptoms (and no variance
in respiratory symptoms). The final causal model of influenza im-
pact is shown in Figure 3.
Further analysis indicated that the same measurement model
fitted the data from both confirmed influenza and ILI groups. This
indicates that data collected from these samples could be pooled
and that the questionnaire is appropriate for both ILI and con-
firmed influenza. This analysis was a simple two-group measure-
ment model split by influenza status with all factor loadings, fac-
tor correlations, and correlated residuals constrained to be equal
across groups. Fit statistics for this two-group model (N  258)
were 2  761.91, 608 df, P  0.0001; 2/df  1.25; CFI  0.989; TLI 
Fig. 3 – Structural equation model of the overall impact of in
.0001; 2/df = 1.73; root mean square error of approximatio
.983; weighted root mean square residual = 0.915. Confirm.992; RMSEA  0.044; WRMR  1.289.Rasch analysis
Symptom domain. Using Rasch analysis, the 10-item symptom
domain had satisfactory threshold ordering, but the overall fit be-
tween the domain and the Rasch model was poor, 2(20)  95.78,
 0.001. Items headache and fatigue also showed evidence of
IF, with female subjects obtaining higher scores on these items
han male subjects with comparable levels of symptom severity
P  0.001). Items cough, sore throat, and nasal congestion had
esiduals ranging between 2.52 (nasal congestion) and 4.15 (sore
hroat) and were also misfitting on the 2 test, suggesting that
these items were not measuring the same construct as the rest of
scale items. One additional item (body aches and pains) had a high
negative residual (2.53), suggesting redundancy.
Consistent with the results of CFA, PCARC showed that the
items cough, sore throat, and nasal congestion had high positive
loadings on the first principal component, whereas the remaining
items had low or negative loadings, thus indicating nonunidimen-
sionality of the symptomsdomain.The itemswere thensplit into the
za on affected people. Fit statistics: 2 = 498.23, 288 df, P <
.053; confirmatory fit index = 0.985; Tucker-Lewis index =
u =1, influenza-like illness = 2.fluen
n = 0
ed flsystemic and respiratory symptom domains. The systemic symp-
t
t
t
fi
y
f
h
e
t
n
g
m
a
i
fi
0
e
w
696 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9toms domain had good measurement properties, including overall
fit, PSI, ordered thresholds, and no misfitting items or DIF (Table 2).
The respiratorydomainhadgoodoverallmodel fit andnodisordered
thresholds but cough had some evidence of DIF, with higher scores
obtained by individualswith confirmed influenza comparedwith ILI.
Impact on daily activities and impact on emotions domains. The
impact on daily activities and impact on emotions domains per-
formed very well across most fit indices (Table 2). The only excep-
tions were “prepare meals/get your own food” (fit residual 3.07)
and “get out of bed” (fit residual 2.73) items of the impact on daily
activities domain. Removing these items did not substantively im-
prove fit; therefore, they were retained.
Impact on others domain. Although the overall Raschmodel fit for
he impact on others domain was weak (Table 2), two critical fac-
ors were very good; PSI was 0.90 and there were no disordered
hresholds.
“Being a burden” and “people being annoyed with you” hadmis-
tting residuals and significant 2 test result. “Peopleworrying about
ou” had a fit residual of 3.12 and “people having to do extra things
or you”misfittedona 2 test (P 0.009). “Peopleworrying about you”
ad some evidence of DIF where older people were more likely to
ndorse higher response options than younger people. PCARC failed
o identify distinct subdimensions among the items. Model fit was
ot substantially improved by removingmisfitting items, either sin-
ly or in various combinations; therefore, they were retained in the
easure.
Internal consistency
Internal consistency using Cronbach’s was good or excellent for
ll domains except for respiratory symptoms, which only had 3
tems (Table 4).
Convergent and discriminant validity
The Spearman’s correlation coefficients between the FluiiQ™ and
the other measures are shown in Table 5. As hypothesized, the
FluiiQ™ and the Patient GSQ had moderate to high correlations
(range, r  0.35–0.71) at all three time points, except for one coef-
cient, which was below the expected range (day 1, r  0.22 with
impact on others domain). In addition, themajority of correlations
with theGGHQand theEQ5D thermometerwere in thehypothesized
direction (positivewithGGHQandnegativewithEQ5D thermometer)
and in the moderate range (r 0.25). Overall, weak associations (r
Table 5 – Spearman’s correlation coefficients between Flui
Symptoms
All Systemic
Patient global severity question
Day 1 0.44 0.41
Day 7 0.60 0.53
Day 14 0.68 0.56
Physician global severity question
Day 1 0.21 0.22
Day 14 0.40 0.32
EQ5D thermometer
Day 1 0.27 0.27
Day 14 0.41 0.39
Generic global health question
Day 1 0.23 0.24
Day 7 0.48 0.45
Day 14 0.43 0.40.25) were observed between the FluiiQ™ and the Physician GSQ,specially at day 1. In general, for allmeasures used, the correlations
ere higher on days 7 and 14 compared to day 1.
Known groups validity
Known groups validity was supported because those with con-
firmed influenza had a higher score than those with ILI across all
domains, as expected (Table 4). The 95% CI for difference, how-
ever, included 0 for impact on emotions and impact on others. The
largest mean difference between confirmed influenza and ILI was
for impact on daily activities (mean 0.38; 95% CI 0.12–0.60).
Responsiveness to change
Mean (SD) scores at day 1 across domains ranged from 1.85 (0.63)
for respiratory symptoms to 1.00 (0.85) for impact on others. At day
14, the mean (SD) score ranged from 0.42 (0.57) for respiratory
symptoms to 0.08 (0.25) for both impact on daily activities and
impact on others. Large and rapid changes in mean scores across
all domains were observed across the 14 days (Fig. 4). The largest
mean individual change was for symptoms (all) and respiratory
symptoms, both with changes1.5 units over 14 days. The symp-
toms (all) domain had the largest observed SRM (2.28) and effect
size (2.66). The SRM was 1.0 for all domains, indicating the do-
mains were highly responsive to change.
Discussion
These analyses provided evidence of the validity of the FluiiQ™ as
measures of symptoms severity and impact of influenza. The
FluiiQ™ comprises five new scales that are now available for re-
searchers to assess influenza symptom severity and impact in ep-
idemiological research as well as to explore efficacy and effective-
ness of influenza prophylactic and/or therapeutic agents in
clinical trials. The procedures used to develop the FluiiQ™ fol-
lowed the FDA guidance for PRO development and validation in-
cluding patient and clinician input, explicit conceptual model de-
velopment, cognitive testing, validation in the target population
(confirmed influenza patients) with clear evidence of construct
validity, reliability, and responsiveness [4].
An important constraint considered during the development of
the questionnaire was that it should be short and requireminimal
cognitive capacity to understand and answer the questions reli-
ably given that people with influenza have substantial malaise.
Consequently, each question and response option generated were
conceptually straightforward so that affected individuals are able
domains and other measures.
Impact on
daily activities
Impact on
emotions
Impact on
others
iratory
0.35 0.38 0.35 0.22
0.58 0.48 0.51 0.37
0.71 0.46 0.48 0.36
0.07 0.19 0.10 0.08
0.44 0.18 0.19 0.05
0.15 0.29 0.23 0.19
0.40 0.35 0.37 0.23
0.08 0.24 0.29 0.19
0.40 0.42 0.39 0.36
0.41 0.30 0.29 0.28iQ™
Resp
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697V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9The fit indices in the SEM and Rasch analyses indicate that this
was achieved for almost every item. The high item endorse-
ment, including minimal missing data, high relevance (bother-
omeness) scores for the symptoms questions, and absence of
isordered thresholds indicate that the questions are pertinent
nd people with influenza are able to respond to the question-
aires in a congruent manner. The exception was some redun-
ancy between the “needing to depend on people” and “people
aving to do extra things for you” items in the impact on others
omain. There was also some evidence of weakness in the “being
burden” item. These items, however, were retained to ensure
readth of the impact on others domain; additionally, removal of
ny item did not significantly improve the model fit. Revision and
urther testing of items may improve future versions of the ques-
ionnaire.
The results largely confirm the symptom profile presented in
revious reports [23–25]. The interviews with clinicians and con-
ultation with patients with confirmed influenza and ILI enabled
mportant refinements to be made on the measures and content
alidity to be established. Nausea and lack of concentration were
emoved because these were regarded as not being specific to in-
uenza. Neck pain was added and was found to be a highly
congruent item in the systemic symptoms scale. The careful
consultations that we undertook with patients enabled us to
identify and validate novel measures of the impact of influenza;
these were impact on daily activities, impact on emotions, and
impact on others. These are more downstream effects of influ-
enza, and our SEM analysis provides evidence that they are
causally related to the symptoms.
Importantly, the symptoms and the impact scales performed
well across several indices of validity (both within the FluiiQ™
items and between the FluiiQ™ and other measures included in
the study) and reliability. Each is linked to different rates of change
ver time, which probably reflects the pathophysiological develop-
entand resolutionof thedisease. Impactondailyactivitiesappears
o resolve most quickly, whereas respiratory symptoms begin with
he highest burden and at day 14 remain the highest andmay reflect
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Fig. 4 – Influenza symptomslingeringnaggingcoughandgradual resolutionofnasal congestion.In contrast, systemic symptoms and other impacts have mostly re-
solved by day 14. Although the respiratory symptom domain has
only 3 items and low reliability/PSI, its ability to show change over
time appears reasonable. Despite the small number of somewhat
disparate itemswithin the respiratory symptoms, this domain ap-
pears to work well as a scale, and this is also supported by the
congruent SEM analyses.
Overall, the correlation between the FluiiQ™ and the other
measures included in the validation study were moderate and
therefore demonstrating reasonable convergent validity with
symptoms and measures of well-being. Weaker correlations were
observed between the patient reported FluiiQ™ and the Physician
GSQ, which is a common finding [26,27]. Across all measures, a
lower correlation was observed at day 1 compared to later assess-
ments, which may relate to patients considering their general
health to be good, regardless of their influenza episode.
As shown in Figure 3, the absence of significant paths from
respiratory symptoms to daily activity and impact on emotions
demonstrates that the majority of the effect on these two out-
comes is from the systemic symptoms. The sharp discrimination
between the impact of respiratory and systemic symptoms on the
self-reported impact outcomes also suggests that there is an ab-
sence of a “general response factor” influencing the results (e.g.,
acquiescence, social desirability, or similar biases). In otherwords,
patients appear to consider eachquestion carefully and respond to
its content in a way that is independent from other items in the
domain. Our consultations with patients during the development
work also supported this because we found the respiratory symp-
toms to be ranked somewhat lower on the bothersomeness scale.
The congruence between SEM and the more direct questions
about bothersomeness provide further support for the content
and construct validity of the domains.
The robustness of a five-factor measurement model across the
confirmed influenza/ILI groups provides support that data col-
lected from these two samples can be pooled for analyses. This is
also congruent with physician’s reports that it is difficult to
distinguish true influenza from ILI in the clinical setting. Nu-
8 9 10 11 12 13 14
ry to study (days)
Symptoms (all)
Systemic symptoms
Respiratory symptoms
Impact on daily acvies
Impact on emoons
Impact on others
impact profile over 14 days.7
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698 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 8 7 – 6 9 9fluenza is circulating in a community, ILI, particularly cough
and fever, is predictive of true influenza infection [25,28,29].
ecause our questionnaire development and validation proto-
ols required site confirmation of circulating laboratory-con-
rmed influenza in their geographic region before recruitment
nd enrollment, our findings are not surprising.
An important finding from the perspective of the validity of the
omains is the very strong paths between systemic symptoms and
aily activities and impact on emotions compared to the absence of
ignificant paths from respiratory symptoms to these latent vari-
bles. This clearly suggests that the distinction between respiratory
ymptoms and systemic symptoms has causal validity as well as
actorial validity (convergent and discriminant validity), thus
trengthening the construct validity of the distinction for evalua-
ion purposes. It is plausible that viral infection in the upper respi-
atory areas (nose, throat) and the associated secretions result in
he sore throat and nasal congestion. The secretions then travel
own the respiratory tract, resulting in a dry reactive cough. The
emaining (systemic) symptoms are a result of the immune sys-
em response to the viral load. Interferon and other mediators
re released into the bloodstream and result in the widespread
ymptoms related to the systemic reactions to infectious ill-
ess. Given that there is a clear case for the distinction in the
easurement of respiratory symptoms and systemic symp-
oms and a plausible biological causal path, a summated score
f the 10 symptom items is not recommended. This is supported
y the one-factor model, which does not fit and the correlation
etween the two symptom factors is not sufficiently high (r 
.58) to justify adding up the two subdomains. Although inves-
igators may choose a priori to combine the 10 symptoms as an
utcome, our analyses suggest that separating the domains will
rovide more meaningful data.
The main potential limitation of the FluiiQ™ is the respiratory
omain because of its low reliability. This could possibly be a tar-
et for further development, although it seems unlikely thatmany
ore relevant and independent indicators of this construct can be
enerated. Measurement of test-retest reliability is a challenge in
his area because symptoms of influenza change rapidly and it is
ot possible to select a test-retest period when a respondent has
oth stable symptoms and cannot easily recall their previous an-
wers. We therefore used evidence about a scale’s ability to detect
hange as a way to compensate for lack of information about test-
etest reliability. If a scale is highly unreliable, it would have a poor
bility to detect change overtime. Figure 4 and Table 4 provide
vidence that the respiratory and systemic symptoms scales per-
orm satisfactorily (detect change in a similarmanner) as themag-
itude of change and SD of change is similar. Although concept
apping and other qualitative and quantitative processes under-
aken help to ensure that the impact of influenza is well covered,
nother potential limitation is our a priori exclusion of work and
nancial impacts. Although patient diaries cover these areas in
etail, there may be influenza-specific impacts that we have
issed. Future work should include a focus on these challenging
reas. Finally, another arguable weakness of this study is the rel-
tively small sample size for SEM. This is always a challenge
hen gathering data specifically for questionnaire develop-
ent where there are few cases (rare disease) or the cost of
athering a large sample is prohibitive. A recent simulation
tudy showed that WLSMV estimation of CFA models in Mplus
erformed equally well across a range of sample sizes between
50 and 1000. It was concluded [30] that “Overall, these results
demonstrate that WLSMV estimation does not need the large
sample sizes needed for WLS estimation.” Although this study
was not extended to causal models, it did involve complex CFA
models with moderate factor loadings, thus affirming support
for the clear superiority of WLSMV estimation for CFA with cat-
egorical variables and relatively modest sample sizes.An area for future work is defining the predictive validity of
each FluiiQ™ domain. As mentioned earlier, it would be valuable
to explore which specific FluiiQ™ symptoms or combination of
symptoms predict true influenza or specific strains of influenza. A
tool with high predictive validity could be a useful element in the
surveillance of local outbreaks and even pandemics. Work needs
to be done to explore whether the FluiiQ™ can be used to facilitate
more accurate diagnosis of ILI in the busy clinical setting. It is
likely that, with an increasing score of appropriately weighted
items, there will be an increasing probability of true influenza be-
ing present in an individual. For example, our ILI definition was
taken from clinical efficacy studies evaluating the Live Intranasal
Influenza Vaccine because the ILI definition was much broader
than the Centers for Disease Control and Prevention definition of
fever (37.8°C, 100°F) plus cough, sore throat, or both in the ab-
sence of another known cause of illness, in part because we
wanted to capture as many potential cases as possible. Further
work on the FluiiQ™ could systematize the collection of the symp-
tom profile to improve case definition accuracy. Furthermore, this
may also provide more accurate data on prodromal aspects of
influenza that lead to incapacitation and hospitalization. The
FluiiQ™ is already being used in a variety of large multinational
clinical trials and epidemiological studies, and secondary analysis
from these studies may be used to understand the predictive va-
lidity and cross-cultural validity of the questionnaire. A copy of
the questionnaire may be obtained from the authors.
The use of recommended patient and clinician engagement
processes in the preparation of items and constructs, robust clas-
sic and modern psychometrics, and systematic evaluation of the
items and domains in the target population has generated rigor-
ous data to support the validity of the FluiiQ™ as a measure of
symptom severity and the impact of influenza.
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